Population pharmacokinetics of plasma‐derived factor IX: procedures for dose individualization A Brekkan, E Berntorp, K Jensen, EI Nielsen, S Jönsson Journal of Thrombosis and Haemostasis 14 (4), 724-732, 2016 | 41 | 2016 |
A population pharmacokinetic-pharmacodynamic model of pegfilgrastim A Brekkan, L Lopez-Lazaro, G Yngman, EL Plan, C Acharya, AC Hooker, ... The AAPS journal 20 (5), 91, 2018 | 23 | 2018 |
Model‐based evaluation of low‐dose factor VIII prophylaxis in haemophilia A A Brekkan, J Degerman, S Jönsson Haemophilia 25 (3), 408-415, 2019 | 10 | 2019 |
Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM A Brekkan, S Jönsson, MO Karlsson, EL Plan Journal of Pharmacokinetics and Pharmacodynamics 46, 591-604, 2019 | 7 | 2019 |
Sensitivity of pegfilgrastim pharmacokinetic and pharmacodynamic parameters to product differences in similarity studies A Brekkan, L Lopez-Lazaro, EL Plan, J Nyberg, S Kankanwadi, ... The AAPS Journal 21 (5), 85, 2019 | 2 | 2019 |
Reduced and optimized trial designs for drugs described by a target mediated drug disposition model A Brekkan, S Jönsson, MO Karlsson, AC Hooker Journal of Pharmacokinetics and Pharmacodynamics 45, 637-647, 2018 | 2 | 2018 |
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach A Brekkan, R Lledo-Garcia, B Lacroix, S Jönsson, MO Karlsson, EL Plan Journal of Pharmacokinetics and Pharmacodynamics, 1-11, 2023 | | 2023 |
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc) Y Yu, ME Rothenberg, HT Ding, A Brekkan, G Sperinde, B Harder, ... Journal of Pharmacokinetics and Pharmacodynamics, 1-13, 2023 | | 2023 |
Bimekizumab in moderate-to-severe plaque psoriasis: population pharmacokinetic and pharmacodynamic relationships P Vajjah, C Acharya, A Brekkan, M Zamacona, M Nemansky, L Peterson, ... BRITISH JOURNAL OF DERMATOLOGY 186 (1), E47-E48, 2022 | | 2022 |
Investigating the identifiability of one-stage IVIVC population models for extended-release dosage forms S Zannoni, A Brekkan, G Smania | | |
Model based support to biosimilarity assessment planning–A case study of pegfilgrastim A Brekkan, L Lopez-Lazaro, EL Plan, C Acharya, G Yngman, J Nyberg, ... | | |